New Intralesional Therapy Combinations Are Poised to Expand Beyond the Oncology Setting

Source: Targeted Oncology, June 2020

In the treatment of many advanced cancers, molecular profiling for the detection of tumor mutations and genomic signatures is recognized as the standard of care. But broad adoption of testing methods that allow for assessing all possible actionable targets and diagnostic markers becomes more complex with greater availability of lifesaving targeted therapies.

To keep up with the momentum in the development of precision oncology agents, multigene testing assays have come into focus in certain solid tumors, such as non–small cell lung cancer (NSCLC),1 and with wider availability, these broader testing methods are making headway in the treatment of patients in more clinical settings.

The main disadvantage of traditional companion diagnostics lies in the restriction of testing to 1 bio-marker per drug per tumor. Diseases with multiple potential targets require broader testing, and the growing prevalence of tumor-agnostic drug indica-tions continues to expand this list.2

READ THE ORIGINAL FULL ARTICLE
Menu